Real-world data confirms that the favorable safety profile of CAR T-cell therapies like Obicell holds true in broad clinical practice. This has been a crucial factor in expanding eligibility to older patients, with successful treatments now being administered to individuals in their 70s and 80s.

For older, transplant-ineligible patients, well-tolerated, long-term regimens from trials like CFIUS shift the treatment goal. Success is defined as managing myeloma so effectively that patients are more likely to die of other age-related causes, effectively outliving their cancer.

While scientifically novel, the primary advantage of in vivo CAR-T therapy is its potential to overcome the significant logistical barriers of traditional CAR-T. By simplifying the process to a single injection, it could democratize access for patients far from specialized academic medical centers.

Experts advise referring patients to CAR T centers upon diagnosis, not when they need the therapy. This isn't for a "second opinion" but to establish a collaborative relationship early. This facilitates seamless access and planning when CAR T becomes necessary later.

Contrary to the belief that CAR-T therapies require inpatient hospitalization, about 50% of Carvykti infusions occur in an outpatient setting. This flexibility allows more hospitals to offer the treatment and makes it more accessible for patients, revolutionizing the delivery model for complex cell therapies.

Experts report successfully treating lymphoma patients as old as 92 with CAR-T, even those with mild cognitive impairment. This demonstrates that chronological age alone is not an absolute contraindication; functional status is a more critical determinant of eligibility for intensive therapies.

Without head-to-head trials, clinicians select between Obicell and Brexacel based on a practical algorithm. Patient factors like age and frailty, disease burden, and logistical concerns like product availability dictate the selection, with safer options prioritized for high-risk patients.

The next major shift for CAR T-cell therapy is its integration into frontline treatment. Instead of being reserved for relapse, it's being tested as a consolidation therapy that could replace the standard two to three years of maintenance chemotherapy, dramatically shortening treatment duration.

Experts vehemently state that patients ineligible for autologous stem cell transplant are not necessarily ineligible for CAR-T therapy. This corrects a critical misconception, urging community oncologists to refer these patients for CAR-T evaluation as they may still be candidates.